SCHEMBL4176434

SCHEMBL4176434

CC(C)(C)OC(=O)N1CCc2cc(N3CC[C@H](N)C3=O)c(F)cc2C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.53
ESR2 Q92731 1/20 0.48
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
MAP3K5 Q99683 1/20 0.39
GPR119 Q8TDV5 2/20 0.38
DPP4 P27487 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HPGDS O60760 1/20 0.38
KDM1A O60341 1/20 0.37
HRH3 Q9Y5N1 4/20 0.37
ADORA1 P30542 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
MAPK1 P28482 1/20 0.36
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4178857 0.89 NR1H2 (0.54) NR1H2ESR2DDB1CRBNMAP3K5
SCHEMBL4171693 0.88 NR1H2 (0.53) NR1H2ESR2DDB1CRBNGPR119
SCHEMBL8257610 0.82 NR1H2 (0.55) NR1H2ESR2DDB1CRBNMAP3K5
SCHEMBL4171451 0.82 NR1H2 (0.64) NR1H2ESR2DDB1CRBNGPR119
SCHEMBL4172281 0.82 ESR2 (0.58) NR1H2ESR2DDB1CRBNGPR119
SCHEMBL4171919 0.82 ESR2 (0.58) NR1H2ESR2DDB1CRBNGPR119
SCHEMBL4183601 0.81 NR1H2 (0.49) NR1H2ESR2DDB1CRBNGPR119
SCHEMBL17065001 0.79 NR1H2 (0.65) NR1H2ESR2DDB1CRBNMAP3K5
SCHEMBL4171400 0.79 NR1H2 (0.65) NR1H2ESR2DDB1CRBNMAP3K5
SCHEMBL31067606 0.79 NR1H2 (0.65) NR1H2ESR2DDB1CRBNMAP3K5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099231-A1 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors GLAXO GROUP LIMITED (GB) 2009-04-16 US disclosed
US-20090099231-A1 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors GLAXO GROUP LIMITED (GB) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099231-A1 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors TFPI, SERPINC1, SERPINE1 NR1H2 3160/4885ESR2 3298/4885DDB1 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.